Perioperative anticoagulant therapy in a patient with congenital antithrombinIII deficiency undergoing posterior spinal fusion

Kota Kubo, Eiki Hatori, Tomohiro Suhara, Takashige Yamada, Nobuyuki Katori, Tatsuya Yamada, Hiroshi Morisaki, Junzo Takeda

Research output: Contribution to journalArticle

Abstract

A 22-year-old female was scheduled to undergo posterior thoracolumbar spinal fusion. She had been diagnosed with congenital antithrombinIII (AT-III) deficiency by the onset of pulmonary embolism and deep vein thrombosis after the first operation at the age of 18. Thereafter she had taken warfarin, 5 mg daily, until 4 days before the surgery. Preoperatively, we administered AT-III products to regulate AT-III activity. The posterior spinal fusion was performed successfully without surgical complications. Postoperatively, we continued administration of AT-III products to maintain AT-III activity above 75%. We also used low dose unfractionated heparin with AT-III by continuous intravenous infusion. Heparin was administered with dose adjustment to achieve a target activated partial thromboplastin time of 45 to 60 seconds. After the activated partial thromboplastin time was stabilized in the target range, we started warfarin therapy (target international normalized ratio, 1.5 to 2.5) on postoperative day 16 and stopped administration of heparin on postoperative day 19. There was no thrombosis complications during the perioperative period. Good anticoagulant management was achieved in a patient with congenital AT-III deficiency undergoing posterior spinal fusion.

Original languageEnglish
Pages (from-to)714-717
Number of pages4
JournalJapanese Journal of Anesthesiology
Volume62
Issue number6
Publication statusPublished - 2013 Jun

Fingerprint

Spinal Fusion
Anticoagulants
Heparin
Partial Thromboplastin Time
Warfarin
Perioperative Period
International Normalized Ratio
Ambulatory Surgical Procedures
Pulmonary Embolism
Intravenous Infusions
Venous Thrombosis
Thrombosis
Therapeutics

Keywords

  • Anticoagulant therapy
  • Congenital antithrombinIII deficiency
  • Deep vein thrombosis
  • Pulmonary embolism
  • Spinal fusion

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

Perioperative anticoagulant therapy in a patient with congenital antithrombinIII deficiency undergoing posterior spinal fusion. / Kubo, Kota; Hatori, Eiki; Suhara, Tomohiro; Yamada, Takashige; Katori, Nobuyuki; Yamada, Tatsuya; Morisaki, Hiroshi; Takeda, Junzo.

In: Japanese Journal of Anesthesiology, Vol. 62, No. 6, 06.2013, p. 714-717.

Research output: Contribution to journalArticle

@article{f9f04457a3bc4a8aa86d9427130a136f,
title = "Perioperative anticoagulant therapy in a patient with congenital antithrombinIII deficiency undergoing posterior spinal fusion",
abstract = "A 22-year-old female was scheduled to undergo posterior thoracolumbar spinal fusion. She had been diagnosed with congenital antithrombinIII (AT-III) deficiency by the onset of pulmonary embolism and deep vein thrombosis after the first operation at the age of 18. Thereafter she had taken warfarin, 5 mg daily, until 4 days before the surgery. Preoperatively, we administered AT-III products to regulate AT-III activity. The posterior spinal fusion was performed successfully without surgical complications. Postoperatively, we continued administration of AT-III products to maintain AT-III activity above 75{\%}. We also used low dose unfractionated heparin with AT-III by continuous intravenous infusion. Heparin was administered with dose adjustment to achieve a target activated partial thromboplastin time of 45 to 60 seconds. After the activated partial thromboplastin time was stabilized in the target range, we started warfarin therapy (target international normalized ratio, 1.5 to 2.5) on postoperative day 16 and stopped administration of heparin on postoperative day 19. There was no thrombosis complications during the perioperative period. Good anticoagulant management was achieved in a patient with congenital AT-III deficiency undergoing posterior spinal fusion.",
keywords = "Anticoagulant therapy, Congenital antithrombinIII deficiency, Deep vein thrombosis, Pulmonary embolism, Spinal fusion",
author = "Kota Kubo and Eiki Hatori and Tomohiro Suhara and Takashige Yamada and Nobuyuki Katori and Tatsuya Yamada and Hiroshi Morisaki and Junzo Takeda",
year = "2013",
month = "6",
language = "English",
volume = "62",
pages = "714--717",
journal = "Japanese Journal of Anesthesiology",
issn = "0021-4892",
publisher = "Kokuseido Publishing Co. Ltd",
number = "6",

}

TY - JOUR

T1 - Perioperative anticoagulant therapy in a patient with congenital antithrombinIII deficiency undergoing posterior spinal fusion

AU - Kubo, Kota

AU - Hatori, Eiki

AU - Suhara, Tomohiro

AU - Yamada, Takashige

AU - Katori, Nobuyuki

AU - Yamada, Tatsuya

AU - Morisaki, Hiroshi

AU - Takeda, Junzo

PY - 2013/6

Y1 - 2013/6

N2 - A 22-year-old female was scheduled to undergo posterior thoracolumbar spinal fusion. She had been diagnosed with congenital antithrombinIII (AT-III) deficiency by the onset of pulmonary embolism and deep vein thrombosis after the first operation at the age of 18. Thereafter she had taken warfarin, 5 mg daily, until 4 days before the surgery. Preoperatively, we administered AT-III products to regulate AT-III activity. The posterior spinal fusion was performed successfully without surgical complications. Postoperatively, we continued administration of AT-III products to maintain AT-III activity above 75%. We also used low dose unfractionated heparin with AT-III by continuous intravenous infusion. Heparin was administered with dose adjustment to achieve a target activated partial thromboplastin time of 45 to 60 seconds. After the activated partial thromboplastin time was stabilized in the target range, we started warfarin therapy (target international normalized ratio, 1.5 to 2.5) on postoperative day 16 and stopped administration of heparin on postoperative day 19. There was no thrombosis complications during the perioperative period. Good anticoagulant management was achieved in a patient with congenital AT-III deficiency undergoing posterior spinal fusion.

AB - A 22-year-old female was scheduled to undergo posterior thoracolumbar spinal fusion. She had been diagnosed with congenital antithrombinIII (AT-III) deficiency by the onset of pulmonary embolism and deep vein thrombosis after the first operation at the age of 18. Thereafter she had taken warfarin, 5 mg daily, until 4 days before the surgery. Preoperatively, we administered AT-III products to regulate AT-III activity. The posterior spinal fusion was performed successfully without surgical complications. Postoperatively, we continued administration of AT-III products to maintain AT-III activity above 75%. We also used low dose unfractionated heparin with AT-III by continuous intravenous infusion. Heparin was administered with dose adjustment to achieve a target activated partial thromboplastin time of 45 to 60 seconds. After the activated partial thromboplastin time was stabilized in the target range, we started warfarin therapy (target international normalized ratio, 1.5 to 2.5) on postoperative day 16 and stopped administration of heparin on postoperative day 19. There was no thrombosis complications during the perioperative period. Good anticoagulant management was achieved in a patient with congenital AT-III deficiency undergoing posterior spinal fusion.

KW - Anticoagulant therapy

KW - Congenital antithrombinIII deficiency

KW - Deep vein thrombosis

KW - Pulmonary embolism

KW - Spinal fusion

UR - http://www.scopus.com/inward/record.url?scp=84879187188&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879187188&partnerID=8YFLogxK

M3 - Article

C2 - 23815000

AN - SCOPUS:84879187188

VL - 62

SP - 714

EP - 717

JO - Japanese Journal of Anesthesiology

JF - Japanese Journal of Anesthesiology

SN - 0021-4892

IS - 6

ER -